Decheng Capital LLC Crinetics Pharmaceuticals, Inc. Transaction History
Decheng Capital LLC
- $466 Billion
- Q4 2024
A detailed history of Decheng Capital LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Decheng Capital LLC holds 167,958 shares of CRNX stock, worth $5.77 Million. This represents 1.84% of its overall portfolio holdings.
Number of Shares
167,958
Previous 157,958
6.33%
Holding current value
$5.77 Million
Previous $8.07 Billion
6.39%
% of portfolio
1.84%
Previous 1.91%
Shares
2 transactions
Others Institutions Holding CRNX
# of Institutions
255Shares Held
89.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$312 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$239 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$214 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$211 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$186 Million0.03% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.85B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...